Truist Securities Reiterates Buy on Biomarin Pharmaceutical, Maintains $140 Price Target
Portfolio Pulse from Benzinga Newsdesk
Truist Securities analyst Robyn Karnauskas has reiterated a 'Buy' rating on Biomarin Pharmaceutical (NASDAQ:BMRN) and maintained a price target of $140.
September 25, 2023 | 12:30 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Biomarin Pharmaceutical's stock has been reiterated as a 'Buy' by Truist Securities with a maintained price target of $140.
The reiteration of the 'Buy' rating and the maintenance of the price target by Truist Securities indicates a positive outlook for Biomarin Pharmaceutical. This could potentially lead to an increase in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100